Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388)

作者:Herting Frank; Herter Sylvia; Friess Thomas; Muth Gunther; Bacac Marina; Sulcova Jitka; Umana Pablo; Dangl Markus; Klein Christian
来源:European Journal of Haematology, 2016, 97(5): 461-470.
DOI:10.1111/ejh.12756
  • 出版日期2016-11

全文